Darunavir (formerly TMC114) is a second-generation, sulfonamide-based, peptidomimetic protease inhibitor (PI) with a modified 3-dimensional structure enabling more efficient binding to HIV protease. It has become an important drug, in combination with low-dose ritonavir boosting, in the treatment of both antiretroviral-naïve and multiclass-experienced patients. Growing data now exist suggesting it possesses a high barrier to resistance and requires multiple PI mutations in order to suffer reduced virological potency.
CITATION STYLE
Wolfe, C., & Wolfe, C. (2009). Profile of darunavir in the management of treatment-experienced HIV patients. HIV/AIDS - Research and Palliative Care, 13. https://doi.org/10.2147/hiv.s4842
Mendeley helps you to discover research relevant for your work.